查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853243

不孕症治疗市场按产品类型、治疗类型、诊断和最终用户划分 - 全球预测 2025-2032

Infertility Treatment Market by Product Type, Treatment Type, Diagnosis, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，不孕症治疗市场规模将成长 143 亿美元，复合年增长率为 11.61%。

主要市场统计数据
基准年2024年 59.3亿美元
预计年份：2025年 65.8亿美元
预测年份 2032 143亿美元
复合年增长率（%） 11.61%

从策略层面介绍临床进展、病患行为转变和营运压力如何重新定义整个医疗保健相关人员生育治疗的优先事项。

不孕症治疗领域正经历临床创新、患者人口结构变化和护理服务模式演变的融合，这共同为医疗保健提供者、供应商和支付方带来了机会和挑战。

在临床方面，检测设备、冷冻保存通讯协定和辅助疗法的进步提高了治疗週期效率，并为过去难以治癒的病例拓展了治疗选择。同时，患者的期望也在改变。日益增强的意识、延迟交付以及对个人化诊疗路径的需求，促使医疗机构拓展服务范围，并加大对病患体验的投入。在经济方面，资源分配压力和不稳定的报销政策要求诊所和医院在设备和耗材的资本投资与营运效率提升之间取得平衡。因此，相关人员必须将临床优先事项与切合实际的经营模式结合，以维持成长并取得可衡量的成果。

一场变革性的转变将重新定义整个生育生态系统的临床实践、供应链韧性、以病人为中心的服务以及政策奖励。

生育治疗领域正在发生变化，这些变化同时也改变临床实务、供应链和照护模式。

首先，实验室自动化和数位成像技术正在加速生产，同时提高胚胎培养工作流程的一致性。这些技术变革迫使诊所重新思考人员配置模式和培训重点。其次，以患者为中心的趋势，例如扩大生育力保存的可及性、选择性卵子冷冻以及第三方生殖服务的使用增加，正在重塑需求模式，并提升综合咨询和长期追踪服务的重要性。第三，供应链韧性已成为策略重点。相关人员正在实现关键设备、冷冻保存材料和培养基供应商的多元化，以降低单一来源中断的风险。最后，监管和报销格局正在发生变化，付款人和政策制定者越来越重视基于价值的治疗结果和公平的可及性。

评估近期美国关税措施将如何影响生育治疗价值链中的采购成本、供应链策略和临床准入。

美国最近征收的关税为生育治疗领域的製造商、经销商和临床终端用户带来了新的成本和物流方面的考虑。

对进口实验室设备、专用耗材或零件提高关税，可能会增加培养箱、显微镜、低温系统以及培养基和冷冻保存试剂等设备的到岸成本。为应对此问题，製造商可能会采取本地组装或替代筹资策略，以缓解利润率下降。临床医生和诊所可能面临成本压力，需要调整采购週期、优先采购可重复使用设备或重新协商服务合同，以维持营运预算。同时，传统上整合国际产品线的经销商可能会面临产品组合和前置作业时间的变化。

此外，关税往往会在中期内加速技术替代和供应商整合。拥有现有生产能力的国内製造商将获得谈判优势，而国际供应商则可能凭藉自身竞争力消化关税的影响并维持市场地位。政策制定者和产业协会可能会加强围绕关键临床用品关税豁免的对话，相关人员应准备好提供数据证据，证明关税对患者就医和临床疗效的下游影响。最终，要有效应对关税政策的累积影响，需要协调一致的筹资策略、情境规划以及贯穿整个供应链的清晰沟通，以最大限度地减少对患者照护的干扰。

主导细分市场的洞察，将产品类型、治疗方式、诊断路径和最终用户画像与业务重点和投资选择联繫起来。

对市场区隔进行细緻入微的观点，可以揭示临床需求、资本密集度和耗材依赖性的交会点，从而为相关人员创造差异化的策略要务。

低温系统、气体分析仪、成像系统、培养箱、雷射系统、微操作系统、显微镜、卵子抽吸泵、精子分析系统和精子分离器各自都有不同的生命週期、维护和培训要求，这些都会影响诊所的运作模式和长期预算。配件、介质和消耗品（包括冷冻保存和培养基）具有经常性成本流，会影响供应商关係和库存管理实践。从治疗类型的角度来看，交付模式差异很大：人工授精方法（例如子宫颈内、子宫内和子宫内方法）与辅助生殖技术（例如胚胎冷冻保存、体外受精、卵细胞质内单一精虫显微注射术和胚胎着床前基因诊断）形成对比；不孕症药物—从克罗米芬柠檬酸盐和来曲唑到促性腺激素分泌和二甲双胍－需要药理途径和监测；节育手术，例如子子宫镜检查、腹腔镜检查、肌瘤摘除术和精索静脉曲张治疗，需要不同的转诊流程和手术全期资源。女性不孕症检查依赖造影和排卵检测，而男性不孕症评估则依赖血液检查、精液分析和睪丸切片检查，每种诊断途径都决定了实验室的优先事项和患者咨询。最后，最终用户——冷冻库、生育诊所、医院和研究机构——各自的采购週期、监管义务和服务等级协议要求也各不相同。综合以上细分框架，可以清楚看出，对专用设备、耗材供应保障、员工培训和病患教育的投资将对业务产生最大的影响。

区域分析揭示了人口趋势、报销框架和当地能力将如何影响主要全球市场的采用率和可及性。

区域动态塑造了全球生育治疗领域的需求模式、监管方式和竞争格局。

在美洲，私人诊所网路和完善的报销体系支撑着先进辅助生殖技术（ART）的高普及率，并维持着专用设备和耗材的持续市场。相反，在欧洲、中东和非洲，监管和报销环境各不相同，领先的诊所在都市区推动创新，而不同地区的医疗服务可近性也存在差异。在亚太地区，生育年龄延迟和家庭收入成长等人口趋势正在扩大患者群体，并推动设备和耗材的快速普及。在所有地区，可藉镜的最佳实践包括对培训、品管和冷冻保存材料的低温运输物流的投资。区域报销政策、智慧财产权系统和本地製造能力将继续是决定新技术推广速度和医疗机构如何建构其服务组合的关键因素。

透过模组化产品平台、策略伙伴关係关係和基于证据的价值提案，打造市场领导的企业策略和竞争行动

对公司行为的策略性解读突显了其在创新、投资组合管理和市场竞争执行方面的差异化方法，而这反过来又决定了其竞争轨迹。

领先的製造商正日益重视模组化设备设计和基于平台的耗材生态系统，以锁定与诊所的长期合作关係，同时提供升级途径以保护客户的投资。服务供应商和诊所营运商正在整合资源并建立策略联盟，以扩大规模、规范临床通讯协定并协商更有利的供应协议。同时，专注于单一创新（例如新型培养基配方或人工智慧影像处理系统）的参与企业正在探索与现有经销商和实验室网路建立合作关係，以加速检验和推广。经销商正在增加附加价值服务，例如培训、预防性保养和整体拥有成本分析，以实现价格以外的差异化竞争优势。总而言之，投资于监管策略、临床证据产生和上市后真实世界结果追踪的公司，可以透过减少实施摩擦并向临床医生和支付者展示实际利益来获得竞争优势。

为领导者提供切实可行的建议，以协调技术投资、供应链韧性、实证实践和以患者为中心的服务，从而确保竞争优势。

透过协调商业、临床和营运策略，行业领导者可以利用当前趋势，并在患者就医和治疗效果方面实现可衡量的改进。

首先，领导者应投资可扩展的实验室自动化和培训项目，以提高吞吐量并维持品质。将设备升级与标准化流程和基于能力的员工发展相结合，可以帮助诊所减少週期波动并提高成本效益。其次，企业应实现供应链多元化，并寻求关键耗材和设备零件的近岸外包或双重采购，以降低关税和物流风险。第三，相关人员必须透过赞助强有力的临床研究和真实世界数据倡议来加强证据生成，以展示疗效比较并为与支付方的对话提供资讯。最后，企业应扩展以患者为中心的服务，例如综合咨询、长期存檔服务和数位互动工具，以区分不同的诊疗路径并在患者生命週期中创造价值。这些措施的结合将使医疗服务提供者和供应商能够在保持成长的同时，提高临床可靠性和病患满意度。

采用透明的混合方法研究途径，结合一手访谈、二手检验和三角测量，以提供可靠的产业洞察和策略指南。

本分析所依据的调查方法结合了定性和定量方法，以确保方法的稳健性和透明性，从而得出可操作的结论。

主要研究包括对临床医生、实验室主任、采购经理以及医疗设备製造商和经销商的高级管理人员进行结构化访谈，以获取关于临床工作流程、采购重点和新出现的痛点的第一手观点。次要研究涵盖同行评审的临床文献、监管文件、器械手册和公开的政策文件，以检验技术性能特征和合规性考虑因素。跨资料来源的三角验证实现了对结论的交叉检验，方法论上的保障措施包括标准化的访谈指南、编码员对定性输入的整合以及对供应链和政策影响情境的敏感性分析。在适当情况下，将行业术语和细分框架映射到临床路径，以确保产品和治疗类别与实际应用相符。儘管调查方法的局限性包括不同地区监管透明度的差异以及不断变化的关税和报销政策可能带来的短期不确定性，但这种混合方法仍然为战略规划和营运决策提供了可靠的基础。

总结全文，重点在于技术采纳、供应链韧性、实证实践和以病人为中心的服务模式之间的策略一致性。

总之，由于技术的成熟、患者期望的改变以及对供应链和政策的日益严格审查，生育保健生态系统正处于曲折点。

积极协调实验室自动化、人才培养、供应链韧性和实证医学等方面投资的相关人员，将能够以永续的成本结构提供更高品质的医疗保健服务。此外，差异化的以患者为中心的服务以及与支付方清晰的价值沟通，是扩大医疗服务覆盖范围和确保长期需求的关键槓桿。采购和策略伙伴关係的灵活性将决定哪些机构能够在监管和收费环境不断变化的情况下，保护净利率并维持临床服务的连续性。这些动态的综合作用将为产品开发、临床服务模式和商业性执行方面的创新创造机会，并奖励那些能够将技术进步转化为患者疗效显着改善的企业。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大个人化基因筛检的应用范围，以提高试管婴儿成功率并缩短治疗週期
  • 利用穿戴式感测器技术开发一种非侵入式生殖监测设备，用于即时追踪排卵情况
  • 扩大为癌症患者提供的生育力保存服务，将冷冻保存和不孕症咨询结合
  • 将人工智慧融入胚胎选择过程，以提高试管婴儿诊所的胚胎着床率
  • 生育诊所和远端医疗平台之间的合作日益增多，旨在改善远距患者就医和获得支援。
  • 社会计划生育和单亲家庭趋势推动了对卵子和精子捐赠库的需求激增。
  • 家用荷尔蒙检测套组的出现为传统的临床评估提供了经济有效的替代方案。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依产品类型分類的生育治疗市场

  • 配件
  • 装置
    • 低温系统
    • 气体分析仪
    • 影像系统
    • 培养箱
    • 雷射系统
    • 微型机械手臂系统
    • 显微镜
    • 卵子吸泵
    • 精子分析系统
    • 精子分离装置
  • 介质和耗材
    • 冷冻保存培养基
    • 培养基

第九章：依治疗类型分類的不孕症治疗市场

  • 人工授精
    • 子宫颈内人工授精
    • 输卵管内授精
    • 子宫内人工授精
  • 辅助生殖技术（ART）
    • 胚胎冷冻保存
    • 体外受精（IVF）
    • 卵细胞质内单一精虫显微注射术（ICSI）
    • 胚胎着床前遗传学诊断（PGD）
  • 生育药物
    • 克罗米芬柠檬酸盐
    • 促性腺激素分泌
    • 来曲唑
    • 二甲双胍
  • 不孕症治疗手术
    • 子宫镜检查
    • 腹腔镜检查
    • 子宫肌瘤切除术
    • 静脉曲张修復
    • 静脉曲张切除术

第十章：依诊断分類的不孕症治疗市场

  • 女性不孕症
    • 造影（HSG）
    • 排卵测试
  • 男性不孕
    • 血液检查
    • 精液分析
    • 睪丸切片检查

第十一章 以最终用户分類的生育治疗市场

  • 冷冻库
  • 不孕不育诊所
  • 医院
  • 研究机构

第十二章 生育治疗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 按群体分類的生育治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国生育治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Bayer AG
    • City Fertility Centre
    • CooperSurgical, Inc.
    • Cryoport Systems, LLC.
    • Embryolab
    • Ferring International Center SA
    • FUJIFILM Irvine Scientific, Inc.
    • Genea Group
    • IVI AMERICA, LLC
    • Merck KGaA
    • Monash IVF
    • New Hope Fertility Clinic
    • Nova IVF Fertility
    • NOW-fertility SA
    • Ovum Woman and Child specialty Hospital
    • ReproTech LLC
    • Seegene, Inc.
    • TMRW Life Sciences, Inc.
    • Vitrolife Sweden AB
Product Code: MRR-3E32260F8122

The Infertility Treatment Market is projected to grow by USD 14.30 billion at a CAGR of 11.61% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.93 billion
Estimated Year [2025] USD 6.58 billion
Forecast Year [2032] USD 14.30 billion
CAGR (%) 11.61%

A strategic introduction to how clinical advances, patient behavior shifts, and operational pressures are redefining infertility treatment priorities across healthcare stakeholders

The infertility treatment landscape is experiencing a convergence of clinical innovation, shifting patient demographics, and evolving care delivery models that together create both opportunity and complexity for providers, suppliers, and payers.

Clinically, advances in laboratory instrumentation, cryopreservation protocols, and adjunctive therapeutics are enhancing cycle efficiency and expanding treatment options for previously refractory cases. At the same time, patient expectations are changing; greater awareness, delayed childbearing, and demand for individualized care pathways are prompting providers to broaden service offerings and invest in patient experience. Economically, resource allocation pressures and reimbursement variability require clinics and hospitals to balance capital investments in equipment and consumables with operational efficiency gains. As a result, stakeholders must align clinical priorities with pragmatic business models to sustain growth and deliver measurable outcomes.

Transformative shifts redefining clinical practice, supply chain resilience, patient-centric services, and policy incentives across the infertility treatment ecosystem

The landscape of infertility treatment is shifting in ways that are transforming clinical practice, supply chains, and care models simultaneously.

First, laboratory automation and digital imaging are accelerating throughput while improving consistency of embryology workflows; these technological shifts are prompting clinics to rethink staffing models and training priorities. Second, patient-centric trends such as expanded access to fertility preservation, elective oocyte freezing, and greater uptake of third-party reproduction are reshaping demand patterns and increasing the importance of integrated counseling and long-term follow-up services. Third, supply chain resilience has become a strategic priority: stakeholders are diversifying suppliers for key equipment, cryomaterials, and media to reduce vulnerability to single-source disruptions. Finally, regulatory and reimbursement environments are evolving, with payers and policymakers increasingly focused on value-based outcomes and equitable access, which will influence clinical protocols and investment decisions going forward.

Assessing how recent United States tariff measures influence procurement costs, supply chain strategies, and clinical access within the infertility treatment value chain

Recent tariff actions originating from the United States have introduced new cost and logistical considerations for manufacturers, distributors, and clinical end users in the infertility treatment sector.

Higher duties on imported laboratory equipment, specialized consumables, or component parts can increase landed costs for instruments such as incubators, microscopes, and cryosystems, as well as for culture media and cryopreservation reagents. In response, manufacturers may pursue localized assembly or alternative sourcing strategies to mitigate margin erosion. Clinicians and clinics, facing incremental cost pressures, may adjust procurement cycles, prioritize multi-use equipment, or renegotiate service contracts to preserve operating budgets. In parallel, distributors that historically aggregated international product lines may see shifts in product mix and lead times; they will need to enhance inventory planning and provide clearer total-cost-of-ownership analyses to customers.

Moreover, tariffs tend to accelerate technology substitution and supplier consolidation in the medium term. Domestic producers with existing capacity may gain negotiating leverage, while international suppliers may absorb some duty impacts to retain market presence, depending on competitive dynamics. Policymakers and industry associations will likely intensify dialogue around tariff exemptions for critical clinical supplies, and stakeholders should prepare to provide data-driven evidence of downstream effects on patient access and clinical outcomes. Ultimately, managing the cumulative impact of tariff policy requires coordinated procurement strategies, scenario planning, and clear communication across the supply chain to minimize disruption to patient care.

Segment-driven insights that connect product categories, treatment modalities, diagnostic pathways, and end-user profiles to operational priorities and investment choices

A nuanced view of market segmentation reveals where clinical demand, capital intensity, and consumable dependency intersect and create differentiated strategic imperatives for stakeholders.

When examining product type, equipment categories drive capital expenditure decisions: cryosystems, gas analyzers, imaging systems, incubators, laser systems, micromanipulator systems, microscopes, ovum aspiration pumps, sperm analyzer systems, and sperm separation devices each have distinct lifecycle, maintenance, and training requirements that affect clinic operating models and long-term budgeting. Accessories and media and consumables, including cryopreservation media and culture media, present recurring expense streams and influence vendor relationships and inventory management practices. From the treatment type perspective, delivery models vary considerably: artificial insemination modalities such as intracervical, intratubal, and intrauterine approaches contrast with assisted reproductive technologies that encompass embryo cryopreservation, in vitro fertilization, intracytoplasmic sperm injection, and preimplantation genetic diagnosis; fertility drugs-ranging from clomiphene citrate and letrozole to gonadotropins and metformin-introduce pharmacologic pathways and monitoring needs; and fertility surgeries such as hysteroscopy, laparoscopy, myomectomy, and varicocele interventions create distinct referrals and perioperative resource requirements. Diagnostic segmentation further clarifies care pathways: female infertility investigations rely on hysterosalpingography and ovulation testing, while male infertility assessment centers on blood tests, semen analysis, and testicular biopsy, each diagnostic route dictating laboratory priorities and patient counseling. Finally, end users-cryobanks, fertility clinics, hospitals, and research institutes-exhibit different procurement cycles, regulatory obligations, and expectations for service-level agreements. Taken together, this segmentation framework highlights where investment in specialized equipment, consumable supply security, workforce training, and patient education will deliver the greatest operational leverage.

Regional landscape analysis revealing how demographic trends, reimbursement frameworks, and local capabilities influence adoption and access across principal global markets

Regional dynamics shape demand patterns, regulatory approaches, and competitive positioning across the global infertility treatment landscape.

In the Americas, private clinic networks and an established reimbursement mix support high adoption of advanced assisted reproductive technologies and a sustained market for both specialized equipment and culture media. Conversely, Europe, Middle East & Africa presents heterogeneous regulatory and reimbursement landscapes where leading clinics drive innovation in urban centers while access variability persists across jurisdictions; this region also sees growing interest in fertility preservation and cross-border care. In the Asia-Pacific region, demographic trends including delayed parenthood and rising household incomes are expanding the patient base, driving rapid adoption of equipment and consumables, and prompting domestic manufacturers and international suppliers to adapt product offerings for affordability and scalability. Across all regions, transplantable best practices include investments in training, quality control, and cold-chain logistics for cryopreservation materials. Regional reimbursement policies, intellectual property regimes, and local manufacturing capacity will continue to be primary determinants of how quickly new technologies scale and how providers structure service portfolios.

Corporate strategies and competitive behaviors that differentiate market leaders through modular product platforms, strategic partnerships, and evidence-driven value propositions

A strategic read of company behavior underscores differentiated approaches to innovation, portfolio management, and go-to-market execution that will determine competitive trajectories.

Leading manufacturers increasingly prioritize modular equipment designs and platform-based consumable ecosystems to lock in long-term clinic relationships while offering upgrade pathways that protect customer investments. Service providers and clinic operators are consolidating or forming strategic alliances to achieve scale, standardize clinical protocols, and negotiate more favorable supply contracts. At the same time, entrants focused on single innovations-such as novel culture media formulations or AI-enabled imaging systems-seek partnership models with established distributors and laboratory networks to accelerate validation and adoption. Distribution firms are enhancing value-add services, including training, preventative maintenance, and total-cost-of-ownership analyses, to differentiate beyond price. Across the board, companies that invest in regulatory strategy, clinical evidence generation, and post-market real-world outcome tracking will secure competitive advantage by reducing adoption friction and demonstrating tangible benefits to clinicians and payers.

Actionable recommendations for leaders to align technology investments, supply resilience, evidence generation, and patient-centered services to secure competitive advantage

Industry leaders can capitalize on current trends by aligning commercial, clinical, and operational strategies to deliver measurable improvements in patient access and outcomes.

First, leaders should invest in scalable laboratory automation and training programs that increase throughput while preserving quality; by pairing equipment upgrades with standardized protocols and competency-based staff development, clinics can reduce cycle variability and improve cost efficiency. Second, firms should diversify supply chains and pursue nearshoring or dual-sourcing arrangements for critical consumables and instrument components to mitigate tariff and logistics risks; contracts that include contingency inventory provisions and transparent lead-time commitments will enhance resilience. Third, stakeholders must strengthen evidence generation by sponsoring robust clinical studies and real-world data initiatives that demonstrate comparative effectiveness and inform payer conversations; these data will be pivotal in advancing reimbursement discussions and broadening access. Finally, companies should expand patient-centric services-such as integrated counseling, long-term preservation offerings, and digital engagement tools-to differentiate care pathways and capture value across the patient lifecycle. Taken together, these actions will enable providers and suppliers to sustain growth while improving clinical reliability and patient satisfaction.

Transparent mixed-methods research approach integrating primary interviews, secondary validation, and triangulation to underpin reliable sector insights and strategic guidance

The research approach underpinning this analysis combined qualitative and quantitative techniques to ensure a robust and transparent methodology that supports actionable conclusions.

Primary research included structured interviews with clinicians, laboratory directors, procurement managers, and senior executives across device manufacturers and distributers to capture firsthand perspectives on clinical workflows, procurement priorities, and emerging pain points. Secondary research encompassed peer-reviewed clinical literature, regulatory filings, device manuals, and publicly available policy documents to validate technical performance characteristics and compliance considerations. Triangulation across data sources enabled cross-verification of claims, and methodological safeguards included standardized interview guides, coder-based synthesis of qualitative inputs, and sensitivity analyses for supply chain and policy impact scenarios. Where appropriate, industry terminology and segmentation frameworks were mapped to clinical pathways to ensure that product and treatment categories aligned with real-world practice. Limitations acknowledged in the methodology include variability in regional regulatory transparency and the evolving nature of tariff and reimbursement policies, which can introduce short-term uncertainty; nonetheless, the mixed-methods approach provides a defensible foundation for strategic planning and operational decision-making.

Concluding synthesis that emphasizes strategic alignment across technology adoption, supply resilience, evidence generation, and patient-focused service models

In conclusion, the infertility treatment ecosystem is at an inflection point driven by technological maturation, changing patient expectations, and heightened supply chain and policy scrutiny.

Stakeholders that proactively align investments in laboratory automation, workforce development, supply chain resilience, and evidence generation will be positioned to deliver higher-quality care at sustainable cost structures. Furthermore, differentiated patient-centric services and clear value communication to payers will be critical levers for expanding access and securing long-term demand. As regulatory and tariff landscapes evolve, agility in sourcing and strategic partnerships will determine which organizations can both protect margins and preserve clinical continuity. The combination of these dynamics creates opportunities for innovation across product development, clinical service models, and commercial execution, and it rewards those who translate technological advances into demonstrable improvements in patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of personalized genetic screening to improve IVF success rates and reduce treatment cycles
  • 5.2. Development of noninvasive fertility monitoring devices using wearable sensor technology for real time ovulation tracking
  • 5.3. Expansion of fertility preservation services for cancer patients combining cryopreservation with oncofertility counseling
  • 5.4. Integration of artificial intelligence in embryo selection processes to enhance implantation rates in IVF clinics
  • 5.5. Rising collaborations between fertility clinics and telehealth platforms to increase remote patient access and support
  • 5.6. Surge in demand for egg and sperm donor banking driven by social fertility planning and single parenthood trends
  • 5.7. Emergence of at home hormone testing kits offering cost effective alternatives to traditional clinical assessments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Infertility Treatment Market, by Product Type

  • 8.1. Accessories
  • 8.2. Equipment
    • 8.2.1. Cryosystems
    • 8.2.2. Gas Analyzers
    • 8.2.3. Imaging Systems
    • 8.2.4. Incubators
    • 8.2.5. Laser Systems
    • 8.2.6. Micromanipulator Systems
    • 8.2.7. Microscopes
    • 8.2.8. Ovum Aspiration Pumps
    • 8.2.9. Sperm Analyzer Systems
    • 8.2.10. Sperm Separation Devices
  • 8.3. Media & Consumables
    • 8.3.1. Cryopreservation Media
    • 8.3.2. Culture Media

9. Infertility Treatment Market, by Treatment Type

  • 9.1. Artificial Insemination
    • 9.1.1. Intracervical Insemination
    • 9.1.2. Intratubal Insemination
    • 9.1.3. Intrauterine Insemination
  • 9.2. Assisted Reproductive Technology (ART)
    • 9.2.1. Embryo Cryopreservation
    • 9.2.2. In Vitro Fertilization (IVF)
    • 9.2.3. Intracytoplasmic Sperm Injection (ICSI)
    • 9.2.4. Preimplantation Genetic Diagnosis (PGD)
  • 9.3. Fertility Drugs
    • 9.3.1. Clomiphene Citrate
    • 9.3.2. Gonadotropins
    • 9.3.3. Letrozole
    • 9.3.4. Metformin
  • 9.4. Fertility Surgeries
    • 9.4.1. Hysteroscopy
    • 9.4.2. Laparoscopy
    • 9.4.3. Myomectomy
    • 9.4.4. Varicocele Repair
    • 9.4.5. Varicocelectomy

10. Infertility Treatment Market, by Diagnosis

  • 10.1. Female Infertility
    • 10.1.1. Hysterosalpingography (HSG)
    • 10.1.2. Ovulation Testing
  • 10.2. Male Infertility
    • 10.2.1. Blood Tests
    • 10.2.2. Semen Analysis
    • 10.2.3. Testicular Biopsy

11. Infertility Treatment Market, by End User

  • 11.1. Cryobanks
  • 11.2. Fertility Clinics
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Infertility Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Infertility Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Infertility Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Bayer AG
    • 15.3.2. City Fertility Centre
    • 15.3.3. CooperSurgical, Inc.
    • 15.3.4. Cryoport Systems, LLC.
    • 15.3.5. Embryolab
    • 15.3.6. Ferring International Center S.A.
    • 15.3.7. FUJIFILM Irvine Scientific, Inc.
    • 15.3.8. Genea Group
    • 15.3.9. IVI AMERICA, LLC
    • 15.3.10. Merck KGaA
    • 15.3.11. Monash IVF
    • 15.3.12. New Hope Fertility Clinic
    • 15.3.13. Nova IVF Fertility
    • 15.3.14. NOW-fertility SA
    • 15.3.15. Ovum Woman and Child specialty Hospital
    • 15.3.16. ReproTech LLC
    • 15.3.17. Seegene, Inc.
    • 15.3.18. TMRW Life Sciences, Inc.
    • 15.3.19. Vitrolife Sweden AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFERTILITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS INFERTILITY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA INFERTILITY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. INFERTILITY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. INFERTILITY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INFERTILITY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INFERTILITY TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INFERTILITY TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ACCESSORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ACCESSORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOSYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOSYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOSYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOSYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOSYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOSYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GAS ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GAS ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GAS ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GAS ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GAS ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GAS ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INCUBATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INCUBATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INCUBATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INCUBATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INCUBATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INCUBATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LASER SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LASER SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LASER SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LASER SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LASER SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LASER SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROMANIPULATOR SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROMANIPULATOR SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROMANIPULATOR SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROMANIPULATOR SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROMANIPULATOR SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROMANIPULATOR SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROSCOPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROSCOPES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROSCOPES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROSCOPES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROSCOPES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MICROSCOPES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVUM ASPIRATION PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVUM ASPIRATION PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVUM ASPIRATION PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVUM ASPIRATION PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVUM ASPIRATION PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVUM ASPIRATION PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM ANALYZER SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM ANALYZER SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM ANALYZER SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM ANALYZER SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM ANALYZER SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM ANALYZER SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM SEPARATION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM SEPARATION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM SEPARATION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM SEPARATION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM SEPARATION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SPERM SEPARATION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MEDIA & CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOPRESERVATION MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOPRESERVATION MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOPRESERVATION MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOPRESERVATION MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOPRESERVATION MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOPRESERVATION MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CULTURE MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CULTURE MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CULTURE MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CULTURE MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CULTURE MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CULTURE MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ARTIFICIAL INSEMINATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACERVICAL INSEMINATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACERVICAL INSEMINATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACERVICAL INSEMINATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACERVICAL INSEMINATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACERVICAL INSEMINATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACERVICAL INSEMINATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRATUBAL INSEMINATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRATUBAL INSEMINATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRATUBAL INSEMINATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRATUBAL INSEMINATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRATUBAL INSEMINATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRATUBAL INSEMINATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY (ART), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY EMBRYO CRYOPRESERVATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IN VITRO FERTILIZATION (IVF), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IN VITRO FERTILIZATION (IVF), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IN VITRO FERTILIZATION (IVF), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IN VITRO FERTILIZATION (IVF), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IN VITRO FERTILIZATION (IVF), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY IN VITRO FERTILIZATION (IVF), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION (ICSI), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION (ICSI), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION (ICSI), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION (ICSI), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION (ICSI), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION (ICSI), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS (PGD), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS (PGD), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS (PGD), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS (PGD), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS (PGD), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS (PGD), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CLOMIPHENE CITRATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CLOMIPHENE CITRATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CLOMIPHENE CITRATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CLOMIPHENE CITRATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CLOMIPHENE CITRATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CLOMIPHENE CITRATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GONADOTROPINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GONADOTROPINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GONADOTROPINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GONADOTROPINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GONADOTROPINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY GONADOTROPINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LETROZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LETROZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LETROZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LETROZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LETROZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LETROZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY METFORMIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY METFORMIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY METFORMIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY METFORMIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY METFORMIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY METFORMIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY SURGERIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MYOMECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MYOMECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MYOMECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MYOMECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MYOMECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MYOMECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELE REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELE REPAIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELE REPAIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELE REPAIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELE REPAIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELE REPAIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY VARICOCELECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FEMALE INFERTILITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSALPINGOGRAPHY (HSG), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSALPINGOGRAPHY (HSG), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSALPINGOGRAPHY (HSG), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSALPINGOGRAPHY (HSG), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSALPINGOGRAPHY (HSG), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HYSTEROSALPINGOGRAPHY (HSG), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVULATION TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVULATION TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVULATION TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVULATION TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVULATION TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY OVULATION TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY MALE INFERTILITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY BLOOD TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SEMEN ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SEMEN ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SEMEN ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SEMEN ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SEMEN ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY SEMEN ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TESTICULAR BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TESTICULAR BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TESTICULAR BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TESTICULAR BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TESTICULAR BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY TESTICULAR BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOBANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOBANKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOBANKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOBANKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOBANKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY CRYOBANKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL INFERTILITY TREATMENT MARKET SIZE, BY RESEARCH I